Skip to main navigation Skip to search Skip to main content

Are lazertinib and osimertinib comparable for treating advanced EGFR-mutant non-small cell lung cancer?—insights and limitations from the MARIPOSA study

Original languageEnglish
Article number559
JournalJournal of Thoracic Disease
Volume18
Issue number5
ISSN2072-1439
DOIs
Publication statusPublished - 31 May 2026

Keywords

  • cardiotoxicity
  • Epidermal growth factor receptor-mutant non-small cell lung cancer (EGFR-mutant NSCLC)
  • lazertinib
  • osimertinib

Cite this